2 Pitt研究显示,结合PD1/LAG3免疫疗法,黑瘤治疗效果提高。 2 Pitt research studies reveal enhanced melanoma treatment efficacy with combined PD1/LAG3 immunotherapies.
匹兹堡大学研究人员在《细胞杂志》中的两份研究报告揭示了对针对免疫检查站PD1和LAG3的混合免疫疗法的洞察力。 Two studies by University of Pittsburgh researchers in the Journal of Cell reveal insights into combination immunotherapies targeting immune checkpoints PD1 and LAG3. 这些研究表明CD8+T细胞反应得到加强,与单一疗法相比,用这两种药物治疗的黑皮瘤患者的致癌能力有所提高。 The studies show enhanced CD8+ T cell responses and improved cancer-killing abilities in melanoma patients treated with both drugs compared to monotherapies. 调查结果突出表明,必须了解如何将这些药物结合起来以提高其效力,并建议可将LAG3目标药物即相对抗药性药物与其他免疫疗法结合起来,以加强防治工作。 The findings highlight the importance of understanding how these drugs can be combined to improve their effectiveness and suggest that LAG3-targeting drug, relatlimab, could be combined with other immunotherapies to enhance responses.